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Abstract  
Symptoms related to abnormal gastrointestinal motility and function are common. Oropharyngeal 
and esophageal dysphagia, heartburn, bloating, abdominal pain and alterations in bowel habit are 
amongst the most frequent reasons for seeking medical attention from internists or general 
practitioners, and are also common reasons for referral to gastroenterologists and colorectal 
surgeons. However, the non-specific nature of gastrointestinal symptoms, the absence of definitive 
diagnosis on routine investigations (such as endoscopy, radiology, or blood tests), and the lack of 
specific treatments make disease management challenging. Advances in technology have driven 
progress in the understanding of many of these conditions. This Review serves as an overview for a 
series of Consensus Statements on the clinical measurements of gastrointestinal motility, function 
and sensitivity. A structured, evidence-based approach to the initial assessment and empirical 
treatment of patients presenting with gastrointestinal symptoms will be discussed, followed by an 
outline of the contribution of modern physiological measurement on the management of patients in 
whom the cause of symptoms has not been identified with other tests. Discussions will include 
indications for and utility of high-resolution manometry, ambulatory pH-impedance monitoring, 
gastric emptying studies, breath tests and investigations of anorectal structure and function in  day-
to-day practice and clinical management.  
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Key points 
• Symptoms have poor specificity for gastrointestinal diseases and there is a marked overlap 
between  ‘organic disease’ (including major motility disorders) and functional gastrointestinal 
disease, underlining the need for testing to guide treatment 
• New technology has driven progress, improved our understanding of gastrointestinal 
physiology, and has revolutionized the clinical measurement of gastrointestinal motility and 
function from oropharynx to anorectum  
• Adherence to validated methodology is essential for the assessment of GI motility and 
function, in order to provide meaningful results 
• Diagnoses based on valid, objective metrics (e.g. Chicago Classification for oesophageal 
motility disorders, gastric emptying retention time and colonic transit times) are replacing 
subjective assessment of physiological studies 
• High-resolution manometry has improved the inter-observer agreement and accuracy of 
diagnoses in patients with disorders of oesophageal and anorectal motility and function 
• The importance of abnormal visceral sensitivity has been demonstrated in patients with 
functional gastrointestinal diseases. 
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Glossary 
 
Dysphagia - difficulty or discomfort in swallowing, as a symptom of disease 
Achalasia - a condition in which the lower oesophageal sphincter muscle fails to relax, preventing 
food from passing from the esophagus into the stomach 
High-resolution manometry - a diagnostic system that measures intraluminal pressure activity 
from the throat to the stomach using a series of closely spaced pressure sensors. 
Visceral sensitivity - term used to describe the intensity of sensation (for example, fullness or pain) 
induced by stimulation applied to the abdominal organs (viscera). Hypo-sensitivity indicates that 
stimulation induces less intense sensation than normal. Hyper-sensitivity, indicates that 
stimulation induces more intense sensation than normal. 
Intraluminal impedance - a catheter-based method to detect presence of food, fluid or gas within 
the lumen of the esophagus. Measuring impedance at multiple sites (multichannel) allows for 
determination of the direction of movement of esophageal contents. Combined with pH-
measurement this technique is considered the gold-standard for detection of acid and non-acid 
reflux events. 
Oesophagogastric junction - a complex valve composed of an intrinsic, smooth muscle element 
(lower esophageal sphincter, gastric cardia) and an, extrinsic striated muscle element (diaphragm).  
Contraction reserve – term used to describe the increase in esophageal contractility seen in 
response to physiological challenge (for example, multiple rapid swallows, reflux) 
Aerophagia - a condition, thought to be a learned habit, in which excessive air swallowing leads to 
gastric distension and abdominal bloating  
Supragastric belching - a condition, thought to be a learned habit, in which air is repetitively 
sucked into the oesophagus and then immediately expelled (belched) 
Gastrointestinal Scintigraphy – a test in which a radiolabeled substance (for example, eggbeater 
meal) is ingested to provide a non-invasive and quantitative measure of gastric emptying and / or 
oro-caecal transit. 
Gastric accommodation – a term used to describe the relaxation of the stomach (reduction in 
gastric tone and increase in compliance) that follows ingestion of a meal. 
Defecography - a test in which a series of images are taken as a patient goes through the process of 
having a bowel movement to assess for the presence of any structural or functional pathology. 
Biofeedback therapy - a specialist form of physiotherapy used to treat constipation and faecal 
incontinence in which sensors record muscle activity (for example, abdominal wall, anal sphincter) 
and give feedback to the patient to improve technique. 
Rectocele - a herniation (bulge) of the front (anterior) wall of the rectum into the back (posterior) 
wall of the vagina. It occurs when the fibrous tissue between the rectum and the vagina 
(rectovaginal septum) becomes thin and weak over time. 
Intussuception - a process in which a segment of intestine, in this case rectum, telescopes 
(invaginates) into the lower rectum or anal canal, causing structural outlet obstruction and 
difficulty with defecation. 
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Symptoms related to abnormal gastrointestinal  function can occur from the moment food is 
swallowed to the time faeces are expelled from the body (figure 1). Dysphagia [G] , heartburn, 
bloating, abdominal pain and changes to bowel habit are very common in the general population (1). 
A survey published in 2014 reported that the prevalence of GERD, dyspepsia and IBS vary between 5-
15% in European countries.(1) These symptoms are amongst the most frequent reasons for seeking 
medical attention from general physicians and are also common grounds for referral to specialist 
gastroenterologists.(1)  These functional gastrointestinal diseases (FGIDs) impact on activities of daily 
living, reduce work-related productivity and incur high direct and indirect health care costs.(2) 
Indeed, although life expectancy is normal in FGID patients,(3) the burden of disease in terms of 
quality of life can be compared to those with cardiac failure or advanced malignancy.(4)  
The success of modern, scientific medicine is based on identifying and treating the patho-
physiological basis of so-called organic disease (for example neoplasia, inflammation, achalasia and 
other major motility disorders). However, this approach has not been realized in the field of FGIDs. 
The Rome IV criteria published in 2016 classify these conditions based on the presence of specific, 
digestive symptoms for at least 3 months of the 6 months prior to diagnosis, in the absence of other 
diseases on appropriate investigation.(5) This process can include endoscopy (with biopsies), medical 
imaging and laboratory tests to rule out cancer and conditions such as peptic ulceration, celiac 
disease and colitis. For patients with mild symptoms, negative tests provide reassurance and simple, 
symptomatic management might be all that is required (for example, acid suppression, stool 
regulation). However, for those with severe symptoms that persist on therapy, ruling out life-
threatening disease is not sufficient, and referral for specialist investigations of gastrointestinal 
motility and function is often indicated.  
The aim of physiological investigations is to explain the cause of digestive symptoms and establish a 
diagnosis that can guide rational and effective treatment. Until the introduction of high-resolution 
manometry (HRM) about ten years ago, and even today for certain other investigations, it could be 
argued that investigations of gastrointestinal motility and function rarely provided this information. 
As a result, only patients with clinical suspicion of major motility disorders such as achalasia [G], 
severe reflux disease or fecal incontinence under consideration for surgery were referred for tests. 
Even in this group, many diagnoses were subjective and based on the clinical presentation rather 
than the results of physiological measurement.(6) Technological advances have improved the 
reliability and clinical utility of these investigations. The neurogastroenterology and motility 
laboratory now provides measurements not only of motility but also of function in terms of the 
movement (and digestion) of ingested material within the gastrointestinal tract. This approach is 
important because symptoms do not usually occur unless abnormal motility disrupts function. The 
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measurement of visceral sensitivity [G] in clinical practice remains a challenge; however, the ability 
to associate gastrointestinal events (such as contractions, bolus retention, reflux, accelerated or 
delayed colonic transit ) with symptoms provides some indication of how the patient responds to a 
stimulus. This association is important because both hypersensitivity and hyposensitivity are 
frequent causes of symptoms and disease in patients referred for investigation.(7) 
 [H1] Method 
This paper provides an introduction to a series of reviews initiated by the International Working 
Group for Disorders of Gastrointestinal Motility & Function and published by Nature Reviews in 
Gastroenterology and Hepatology. These reviews summarize the state-of-the-art in clinical 
measurement of the pharyngeal swallow, esophageal motility (8), gastro-esophageal reflux disease 
(9), gastric and intestinal function (10) and anorectal continence and defecation (11). The lead 
authors of each review were invited to contribute to the current manuscript. Consensus was 
achieved through careful evaluation and discussion of available literature, and expert agreement 
when recommendations lacked supporting evidence. All authors consented to the final version of the 
manuscript. 
The first part of this paper provides a structured, evidence-based approach to the initial 
management of patients with symptoms related to Disorders of Gastrointestinal Motility & Function. 
The second part outlines the contribution of the neurogastroenterology and motility laboratory to 
the diagnosis and treatment of patients in whom no cause of symptoms or disease has been 
identified on endoscopy, radiology and other appropriate investigations. In the latter section, unless 
otherwise stated, contents were based on the published consensus documents.  
 
 [H1] Initial management 
The primary aim of the initial assessment of patients with gastrointestinal symptoms is to identify 
‘alarm features’ such as dysphagia, anemia or weight loss that could indicate the presence of 
neoplasia, ulceration or inflammation in the digestive tract (Box 1). If present, then it is obligatory to 
perform endoscopy and/or imaging depending on the presenting complaint. Prospective trials and 
meta-analysis indicates that the presence of alarm features is associated with 5-10% risk of life-
threatening disease, compared to 1-2% risk in patients without these markers.(12, 13) Conversely, if 
no symptoms or signs of life-threatening conditions are present, then invasive investigation is not 
necessarily required.(14, 15) Rather, the Rome Criteria recommend that the diagnosis of FGIDs is 
based on clinical presentation and negative results on appropriate tests (Box 2).(5) Although no item 
in the clinical history is diagnostic, there are many features that help to differentiate patients with 
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organic disease and FGID (table 1). One pointer is that patients with a defined etiology tend to have 
discrete symptoms that remain stable over time, whereas those with functional etiology often 
complain of multiple and changeable symptoms (for example, dyspepsia, IBS and fibromyalgia).(16, 
17) Another factor is that patients seeking medical attention for functional gastrointestinal 
symptoms have a ~50% rate of psychiatric disease such as anxiety, depression or somatization, 
compared with ~20% with ‘organic’ conditions (such as peptic ulceration, colitis) and ~10% of the 
general population.(18, 19) Furthermore, the presence of psychosocial stressors (such as 
unemplyment, bereavement) is associated with more frequent complaints of symptoms, more time 
off work and failure to respond to specific management.(20) Many experts ask patients to complete 
standardized questionnaires to ensure that clinically relevant psychopathology in patients wtih FGID 
is recognized early in the diagnostic process.  
After initial assessment, if abnormal gastrointestinal motility and function is considered the probable 
cause of symptoms, then this diagnosis should be communicated to the patient. Patients with 
symptoms and signs suggestive of aspiration or a major motility disorder, especially in association 
with impaired food intake and nutritional health, require early referral to the neurogastroenterology 
and motility laboratory. For the remainder, a trial of empirical treatment is recommended before 
further investigation is considered. A general approach to the initial assessment and management of 
patients is presented (figure 2).  
For esophageal and dyspeptic symptoms a short course of twice daily PPI therapy is 
recommended.(14, 15) Meta-analyses show that acid suppression usually improves symptoms 
related to gastro-oesophageal reflux and can be effective also in functional dyspepsia. (21-23) At the 
same time a test and treat approach for Helicobacter pylori infection is appropriate although the 
effect on symptoms is modest (number needed to treat >10 in placebo-controlled trials).(23)  
For intestinal and colorectal symptoms first-line treatment includes antispasmodic agents (such as 
hyoscyamine), increased dietary fiber or artificial fiber supplements (for example, psyllium 
preparations) and other medications that regulate bowel frequency and consistency (such as 
polyethylene glycol (PEG) for constipation and loperamide for diarrhea).(24) A trial of antiemetic or 
prokinetic medications (for examples, ondansetron, domperidone, stimulant laxatives) can also be 
considered. If initial therapy does not improve symptoms, then low-dose antidepressant therapy 
(such as amitriptyline, mirtazapine or citalopram) has been shown to be effective in a range of 
functional gastrointestinal symptoms, in particular nausea and abdominal pain.(25-27) The benefit of 
these medications is thought to be related primarily to reduction in visceral hypersensitivity; 
however, some antidepressants have effects also on motility. For example, mirtazepine accelerates 
gastrointestinal transit in animal studies,(28) and has been shown to have symptomatic benefits in 
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functional dyspepsia and refractory gastroparesis in small clinical trials.(29, 30) Similarly, 
amitryptiline slows colonic transit and inhibits rectal contractility in patients with fecal 
incontinence.(31) Non-pharmacological therapy is also of proven value and is preferred by many 
patients. This includes: the involvement of dieticians to manage food intolerance(32) and to facilitate 
nutrition in patients with symptomatic gastroparesis through education on the use of small particle 
diets (33); physiotherapists to treat symptoms related to muscle tension in the abdominal wall, 
diaphragm and pelvic floor (for example, bloating, rumination, constipation due to evacuation 
disorders caused by pelvic floor dyssynergia);(34, 35) and therapists to support patients with 
psychiatric co-morbidity (27).  
Many patients in primary care respond well to this simple, empirical management; however, an 
important minority report persistent symptoms during treatment or adverse effects of therapy. In 
these individuals, referral for investigations of gastrointestinal motility and function to assess the 
causes of symptoms is appropriate (Table 2). Others might insist on investigation prior to embarking 
on potentially costly and / or time consuming management (for example, dietary therapy). Increasing 
evidence reviewed for the International Working Group for Disorders of Gastrointestinal Motility and 
Funciton indicates that the results of these tests can identify clinically relevant pathology and guide 
rational management (8-11).  
 
[H1] Disorders of Swallowing  
For oropharyngeal dysphagia and related symptoms (for example, cough related to swallowing), the 
first investigation is a video fluoroscopic swallowing exam, which can visualize the structure and 
function of the oropharynx and document laryngeal penetration or overt aspiration (36). An 
alternative approach favoured by ear nose and throat specialists that can assess laryngopharyngeal 
motor and sensory function is Fiberoptic Endoscopic Evaluation of Swallowing (FEES) (37). However, 
if imaging and endoscopy do not deliver a definitive diagnosis, then HRM, ideally combined with 
impedance, could identify the cause of symptoms and determine the risk of aspiration.(38-40) In the 
future, brain imaging and other neurophysiological tools might enable characterization of the 
sensorimotor integration processes involved in deglutition.(41) It is hoped that an analysis of these 
complex data will identify the mechanism of oropharyngeal dysphagia and direct effective 
management. 
Important progress has been made in the clinical investigation of esophageal dysphagia. Advances in 
catheter technology now provide a near continuous, high-resolution representation of pressure 
activity from the mouth to the stomach (6). Moreover, the combination of manometry with intra-
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luminal impedance [G] enables simultaneous assessment of motility and bolus movement through 
the esophagus.(6, 42) A key insight from these studies is that dysphagia and other symptoms are 
rarely caused by abnormal motility unless it is accompanied by impaired function. 
With the introduction of HRM technology it was necessary to develop a new classification system to 
diagnose esophageal motility disorders. The Chicago-Classification, now in its third iteration,(43) is 
based on objective measurements acquired during a series of ten ’single water swallows’. The 
metrics used in this analysis have been validated in physiological studies of esophageal function.(43) 
The system is hierarchical, with oesophagogastric junction [G] (EGJ) dysfunction considered first 
because failure of the EGJ to relax and/or open in achalasia and outflow obstruction has a greater 
effect on bolus transport than abnormal peristalsis such as spasm or aperistalsis (44). In addition, the 
Chicago classification makes a clear distinction between major motility disorders which are never 
observed in healthy individuals and are always associated with clinical disease, from minor 
abnormalities which are “outside the normal range” but can be observed in patients without 
dysphagia and, occasionally, in healthy individuals. In the former group with conditions such as 
achalasia or spasm there is a clear rationale for treatment directed at correcting the pathology.(43)  
In the latter group, the association of minor motility disorders with patient symptoms is less certain 
and other factors could also be involved (for example, acid reflux, visceral hypersensitivity) (45, 46). 
Compared with conventional manometry with  ≤8 sensors, the assessment of esophageal motility 
using HRM has been shown to have a higher inter-observer agreement and to increase diagnostic 
yield and accuracy for motility disorders.(47-49) The findings also influence clinical management. 
Based on HRM measurements three subtypes of achalasia are defined based on the absence or 
presence of pan-esophageal pressurization (type I and II, respectively) and spasm (type III).(50) This 
classification is used to guide treatment decisions and predicts the outcome of endoscopic and 
surgical management.(50, 51) The effect of this technology on the diagnosis and management of 
achalasia is detailed in a Consensus Statement published in 2017 (8).  
One key weakness of standard HRM studies is that, in the absence of major dysmotility, the results 
do not explain the cause of symptoms because few patients experience dysphagia on swallowing 
small volumes of water (52). Studies have applied HRM, ideally with impedance, to assess 
esophageal function during normal drinking and eating (52-54). This approach can reveal major 
esophageal motility disorders not detected by standard tests (figure 3) (54). For example, a study 
published in 2015 has shown that including a test meal increases the diagnostic yield of HRM for 
clinically relevant outlet obstrution in patients with dysphagia after fundoplication. The majority of 
those with outlet obstruction responded to balloon dilatation of the fundoplication wrap.(55) 
Additionally, the combination of HRM with a test meal can clarify the severity of minor motility 
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disorders and, by associating esophageal dysfunction to symptoms, provide some insight into the 
role of visceral sensitivity in patients with functional dysphagia.(52, 56) Extending HRM observations 
after the meal can also be of interest in patients with therapy resistant reflux and other post-prandial 
symptoms. These observations can differentiate typical reflux events from behavioral disorders such 
as rumination syndrome and supra-gastric belching.(34)  
 
[H1] GERD 
GERD is common worldwide, with at least 1 in 10 of the general population experiencing heartburn 
or acid regurgitation 2-3-times per week.(1) In the absence of alarm symptoms, the initial clinical 
diagnosis of GERD is based on the symptomatic presentation and response to empiric antisecretory 
therapy.(57) Further investigations are indicated in patients with persistent symptoms on treatment 
with high-dose acid suppression (PPIs twice daily), those with alarm symptoms and those under 
consideration for anti-reflux surgery (58, 59). 
Endoscopy is performed to detect mucosal disease in the esophagus and exclude other pathology 
such as peptic ulcer or cancer. Erosive reflux disease (ERD) or Barrett esophagus are present in ~30% 
of patients referred for investigation off PPI treatment, but less than one in ten in patients on acid 
suppressants (60). Non-erosive (or endoscopy negative) reflux disease (NERD) is diagnosed in 
patients with symptoms, but without mucosal erosions or metaplasia on endoscopic 
examination.(57, 61)  
The sensitivity and specificity of a symptomatic diagnosis, including empiric response to PPI therapy, 
is not always consistent with the results of objective measurements of esophageal reflux (62). In a 
large clinical study from 2010, heartburn and acid regurgitation were present in only 49% of patients 
with pathological levels of acid exposure during 48-hr wireless (Bravo) pH-studies;(63) whereas, 
conversely, 23% patients with “typical reflux symptoms” had normal levels of acid exposure.(63) 
Physiological studies are also performed in patients with “atypical” symptoms that can be triggered 
by gastro-oesophageal or supra-oesophageal reflux such as epigastric pain, chronic cough or 
pharyngeal symptoms (for example, hoarseness, sore throat, globus sensation); however, in this 
patient group only ~25% of tests are positive.(64) Overall, the weak association between patient 
symptoms and the presence of pathological reflux highlights the importance of objective 
measurements to differentiate patients with GERD-related symptoms from those with functional 
disease (for example, reflux hypersensitivity) or symptoms unrelated to reflux.  
Esophageal motility testing with HRM can identify a hypotensive EGJ and/or morphological 
abnormalities at the EGJ (hiatus hernia), both of which contribute to the pathophysiology of reflux 
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(65-67). However, transient lower oesophageal sphincter relaxation (TLESR), the most common 
mechanism of reflux, is not evaluated on routine motility testing despite validation of HRM criteria 
for the identification of these events (68). Esophageal clearance of refluxate is optimal with normal 
esophageal peristalsis; whereas, ineffective esophageal motility (fragmented peristalsis, weak 
peristalsis) or absent contractility can contribute to prolonged residence times of esophageal 
refluxate and lead to increased esophageal acid exposure (69, 70). Provocative (or “adjunctive”) 
testing during HRM can be used to identify patients with ineffective motility who can augment 
peristalsis when challenged with repetitive swallowing (multiple rapid swallows, rapid drink 
challenge) or a solid test meal.(54, 71-75) Demonstation of an effective ‘contraction reserve’ [G]  is 
particularly important if antireflux surgery is being considered (72, 73). Characterization of EGJ 
integrity and esophageal body motor function with contraction reserve constitute essential elements 
of motility evaluation in GERD. 
Guidelines recommend that the diagnosis of GERD be based either on ambulatory pH-studies or, 
ideally, combined pH with multiple intraluminal impedance studies (58, 59). The sensitivity of the 
investigation is optimal if PPI medications are stopped at least 7-days prior to the study. The 
advantage of the combined system is that impedance can detect all reflux events, irrespective of 
acidic content, and also indicates the proximal extent of reflux events. In patients that fail to respond 
to PPI therapy, weakly acidic reflux that extends into the proximal esophagus or pharynx is an 
important cause of both “typical” symptoms (especially regurgitation) and “atypical” symptoms 
(especially cough).(64, 76) Additionally, impedance measurements can detect the movement of air 
through the esophagus and document behavioral conditions such as aerophagia [G] and supragastric 
belching [G] that can be the cause of symptoms in patients with otherwise negative results in 
ambulatory reflux studies.(77) Limitations of these ambulatory studies include catheter intolerance 
in ~10% of patients and a similar proportion in whom catheter-related nasopharyngeal discomfort 
disturbs normal eating, work or sleep leading to false-negative results (78, 79). In such situations 
wireless pH-monitoring (Bravo, Medtronic, USA) provides an alternative method that is well 
tolerated by most patients.(78) A further advantage of the Bravo system is that this, catheter-free 
approach enables prolonged (up to 96h) monitoring, which improves the ability to demonstrate an 
association between acid reflux and symptoms.(80) Wireless pH-monitoring studies are reported to 
identify GERD in at least 1 in 3 patients with previously negative catheter-based tests.(79) 
As detailed in an accompanying Consensus Statement by the GERD working group (9), the 
classification of ambulatory reflux studies is based on the presence or absence of pathological acid 
exposure and/or an increased number of reflux events (acid and otherwise) detected by impedance 
measurements and a close temporal association between reflux events and patient symptoms.(81) 
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To compensate for high day-to-day variability in these metrics, the Lyon Consensus from 2018 
recommends that GERD can be diagnosed not only in patients with severe acid exposure (>6% pH <4 
/ 24h), but also in patients with borderline acid exposure (4-6% pH<4/24h) if supported by other data 
(for example, unstable esophago-gastric junction (hiatus hernia), ineffective esophageal motility).(81) 
Reflux hypersensitivity is diagnosed in patients with normal acid exposure and/or number of reflux 
events, but a positive reflux-symptom association. The diagnosis of ‘functional heartburn [G] ’ is 
applied in the remainder of patients with reflux symptoms, but without objective evidence of 
esophageal disease. This classification system is clinically relevant in that it has been shown that 
patients with objective evidence of GERD on physiological measurement have markedly better 
response to medical or surgical therapy (typically 70-90%) than patients with typical symptoms in 
whom acid exposure is normal and the association of reflux events with symptoms is weak or absent 
(typically 30% individuals).(82-85) In the latter group treatment with antidepressants with the aim of 
reducing visceral sensitivity is recommended.  A systematic review of this approach in patients with 
functional esophageal syndromes reported improvement in 23% to 61% of patients compared to 
ongoing PPI therapy alone.(86) 
 
 [H1] Disorders of gastric emptying and digestion  
Abnormal gastrointestinal motility and sensitivity have been documented in a range of conditions such 
as gastroparesis, functional dyspepsia and IBS (87). An accompanying Consensus Statement explores 
a range of technologies used to assess gastric and intestinal function (10). Measurement of delayed or 
accelerated gastric emptying and small intestinal transit times by scintigraphy [G] , 13C breath tests or 
the wireless motility capsule (SmartPill, Medtronic, USA) provide diagnostic information in cases of 
excessively rapid (dumping) or delayed gastric emptying (gastroparesis).(88, 89) To obtain reliable 
results it is essential that validated methodology is applied. For example, solid test meals might be 
more sensitive to gastroparesis, whereas, liquid test meals might better detect acceleration of early 
gastric emptying associated with gastric dumping. The low-fat, ‘eggbeater’ meal [G] is the best-
established test meal used with gastric scintigraphy.(90, 91) Using this method, delayed gastric 
emptying is documented in ~40% of patients with functional dyspepsia and up to 75% of patients with 
chronic unexplained nausea and vomiting.(92-94) An association between dyspeptic symptoms and 
gastric emptying is observed in some, but not all, studies.(94-100) Severely delayed emptying 
(gastroparesis or gastric failure) is associated with post-prandial vomiting, weight loss, poor health 
status and poor outcome of therapy.(94, 101, 102) However, the results do not necessarily predict 
clinical response to metoclopramide, or other prokinetic and antiemetic medications.(103, 104) More 
sophisticated investigations assess gastric accommodation [G], contractility and sensitivity (for 
Fox et al.                                                  Clinical measurement of gastrointestinal motility and function                                                                    
 
   
 
15  
example, gastric barostat, single-photon emission computed tomography (SPECT), MRI). These 
measurements correlate more closely than gastric emptying with patient symptoms (for example, 
postprandial fullness is associated with impaired accommodation and viscera hypersensitivity); 
however, these tests are not widely available and are reviewed elsewhere.(88, 105, 106) Early 
experience with methods that use scintigraphy to document gastric filling (accommodation), 
contractility and emptying with concurrent assessment of patient symptoms show promise in early 
trials.(107, 108)  
Antroduodenojejunal (ADJ) manometry is used to exclude major gastric and intestinal motility 
disorders in patients with severe, therapy-resistant constipation (a contraindication for colectomy) and 
also in patients with suspected intestinal obstruction but with no definitive diagnosis on radiology 
(109). ADJ manometry may also differentiate between myopathic and neuropathic pathology (88). 
Similarly, colonic manometry provides insight into the causes of lower gastrointestinal symptoms and 
disease (110). Unfortunately, these studies are difficult and time consuming (ideally 24h) to perform 
and analyze. For this reason, most clinicians apply non-invasive tests to assess intestinal and colonic 
transit time using scintigraphy, wireless motility capsule or radio-opaque markers (whole-gut transit 
time only). Objective evidence of slow transit indicates the need for more intensive laxative or 
prokinetic therapy. Conversely, if these investigations show normal intestinal and colonic transit, then 
the diagnosis is most likely to be a FGID such as IBS.(111) However, there is a marked and unclear 
overlap between patients with intestinal dysmotility and patients with FGIDs in whom altered 
gastrointestinal motility is only one among several pathological mechanisms responsible for symptoms 
(87, 88). One potential advantage of the wireless motility capsule is that it collects information about 
multiple parameters including gastric, small bowel and colonic transit (that is, function), intra-luminal 
pressure (that is, motility) and pH-measurements (a surrogate for bacterial fermentation in the large 
bowel) (112, 113). This investigation can be performed in office-based practice; however, as yet, it is 
uncertain whether the information acquired can replace scintigraphy, manometry or influence 
management. 
One type of investigation not covered in the consensus document is the Hydrogen Breath test. These 
tests document malabsorption of lactose, fructose and other carbohydrates that are present in the 
diet and can be a cause of bloating, diarrhea and other symptoms, based on the principle that 
hydrogen is not produced by human metabolism, but is a product of bacterial fermentation in the 
gastrointestinal tract (114, 115). In healthy individuals, hydrogen is produced when nutrients are not 
fully absorbed in the small bowel but are fermented in the colon. Rapid diffusion into the blood stream 
and then the lung allows gas produced in the colon to be detected in the breath within 3 min of the 
substrate coming into contact with bacteria.(116) If the increase in breath hydrogen is associated with 
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the onset of typical abdominal symptoms, then the presence of food (for example, lactose) intolerance 
is confirmed. The risk of intolerance increases with the dose and the amount of gas produced by the 
bacteria but also with patient factors.(117, 118)  For example, many patients with lactase deficiency 
and IBS experience bloating, pain and diarrhea after ingestion of 20g lactose (500ml milk); whereas, 
healthy individuals with lactase deficiency tolerate this amount of lactose without difficulty.(117)  
Hydrogen breath tests using glucose or lactulose as the substrate are also used to detect small 
intestinal bacterial overgrowth (SIBO); however, studies have highlighted limitations of these 
investigations (119, 120). False-negative tests are common due to the presence of bacteria that do not 
produce hydrogen and the addition of methane measurements improves sensitivity only slightly (115). 
False positives are common due to high variability in gastrointestinal function and, in the case of 
lactulose, effects of the substrate on intestinal transit time.(121) As a result, the clinical relevance of 
these findings is debated. Some of these limitations can be addressed by combining the lactulose 
hydrogen-breath test with an independent assessment of orocaecal transit time by scintigraphy. This 
approach can differentiate between an early increase in breath hydrogen due to SIBO and rapid 
orocaecal transit time both of which are thought to be causes of symptoms in patients with IBS.(121) 
 
[H1] Disorders of Anorectal Function 
The rectum and anal sphincter act together with the pelvic floor musculature to maintain fecal 
continence and control defecation (122). Problems with anorectal function are common in the general 
community, especially in women that have had children, individuals with previous anorectal surgery 
and in the elderly (123, 124); however, many patients find it embarrassing to describe these problems 
(125). In particular stool incontinence might not be revealed unless specific questions are asked. 
Standard questionnaires and the Bristol Stool Score can be very helpful for this purpose (125, 126).  
As detailed in the accompanying Consensus Statement by the anorectal working group (11), 
physiological investigations are indicated in patients with fecal incontinence, chronic constipation and 
difficulties in passing stool (so-called evacuation disorders) that do not respond to empirical treatment 
with medications that regulate stool consistency and pelvic floor training. It is important to appreciate 
that these disorders frequently co-exist, which will affect management.(127) Clinical investigations of 
anorectal function include endoanal ultrasonography, manometry, measurements of rectal function 
and balloon expulsion. Additionally, defecography [G] can image the structure and function of the 
pelvic floor at rest and during simulated defecation.(128)  
Although less well established than esophageal HRM, anorectal HRM has been shown to document 
the function of the internal and external anal sphincter in more detail than conventional manometry 
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and with a high-degree of inter-observer agreement.(129, 130) In patients with continence problems 
this assessment is combined with endoanal ultrasonography to image the structure of the anal 
sphincter (figure 4). Measurements of rectal function can also be obtained during the same 
investigation, which is important because 20-40% of patients with fecal incontinence have normal anal 
sphincter function but either a small, non-compliant rectum or abnormal rectal sensitivity, both rectal 
hyposensitivity and rectal hypersensitivity impairs the ability to maintain fecal continence (122, 131, 
132). Together, these findings provide important insight into the causes of passive, urge and combined 
incontinence and fecal seepage. The results of these tests can direct specific management. For 
example, specialist biofeedback therapy [G] is often effective for individuals with an intact sphincter 
that are unable to maintain squeeze pressure and also those with urgency related to visceral 
hypersensitivity.(133, 134) By contrast, this form of training is less useful if symptoms are related to 
pathology that cannot be improved by training (for example, weak internal sphincter, grossly impaired 
rectal sensation (134)). Surgical repair of the anal sphincter is usually reserved for patients with a weak 
squeeze pressure related to a large tear in the external sphincter. In others, application of sacral nerve 
stimulation is often effective (135), with follow up of prospectively registered patients reporting 
ongoing improvement in faecal continence in 71% with full continence achieved in 50% at a median of 
7 years after implantation (136). 
In patients with chronic constipation or an evacuation disorder, the balloon expulsion test documents 
the ability of a patient to defecate a small, water-filled balloon from the rectum. If this expulsion is not 
achieved within a set time limit, then this is a marker of impaired evacuation that might be secondary 
to structural or functional abnormalities of the pelvic floor or anal sphincter.(137) Qualitative 
assessment of anorectal function by HRM can detect abnormal anorectal pressure activity and function 
in patients with dyssynergic defecation (for example, paradoxical contraction of the anal sphincter or 
inadequate push effort) with a high level of agreement with the results of MR-defecography.(138) 
However, as yet, valid quantitative measurements of anorectal pressure activity during defecation 
have not been established.(139) Defecography is particularly useful in detecting structural conditions 
that impair the passage of stool.(138) The results of manometry and imaging has direct effect on 
clinical management. If outlet obstruction is related to dyssynergic defecation then biofeedback 
therapy is effective in up to 80% of patients compared to 20% treated with laxatives alone.(140) 
Whereas in those with excessive pelvic floor descent, large retaining rectocele [G] with obstructive 
intussusception [G] or prolapse, surgery is often required to restore functional anatomy. In cases in 
which no pathology is identified, a colonic transit test using Sitzmarks or scintigraphy or the wireless 
motility capsule can be very helpful to confirm slow-transit constipation.(87) If transit is slow, then 
more intensive laxative or prokinetic therapy is required. Conversely, if this test shows normal transit, 
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then the likely diagnosis is IBS or a related FGID with altered awareness of gastrointestinal 
function.(111) In such cases treatments should be targeted towards improving visceral 
hypersensititivty or addressing psychosocial stressors, including a past history of abuse.  
 
Conclusions 
Symptoms related to abnormal gastrointestinal motility and function are very common; however, the 
non-specific presentation, the absence of definitive diagnosis on endoscopy and other tests, the co-
existence of psychosocial issues, and the lack of specific treatments make the management of FGIDs 
challenging. The initial assessment must rule out life-threatening disease and select patients either 
for further investigation or a trial of empirical, symptomatic management. In the past, the role of 
physiological investigations was limited; however, advances in technology and methods can now 
provide more meaningful assessment of gastrointestinal motility and function. Accurate and 
objective measurements enable definitive diagnoses that can have a direct effect on treatment 
decisions in clinical practice. However, even when no specific treatment can be offered, based on the 
results of these tests, a clear explanation of the causes of symptoms can be therapeutic in itself. 
Well-informed patients are more satisfied, cope with their condition better and seek medical 
attention less frequently than those that have not been fully informed.(141)  
Looking ahead (Box 3), new insights from basic and clinical science are needed to better understand 
the pathological basis of disorders of gastrointestinal motility and function. At the same time, there 
is a need for novel investigations and methods that identify not only abnormal motility but also 
abnormal sensitivity. Advances on all of these fronts are required to define patients with specific 
phenotypes of neurogastroenterology and motility diseases that respond to specific treatments.  
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Box 1| Alarm features 
• Dysphagia, bolus obstruction or odynophagia (pain on swallowing) 
• Recurrent vomiting 
• Evidence of blood loss from gastrointestinal tract or iron deficiency anemia 
• Involuntary weight loss (>5% baseline) 
• Abdominal mass or pathological lymph nodes 
• New presentation of digestive symptoms or change in bowel habit in patients aged >45 years 
 
Box  2 | Initial investigations in functional gastrointestinal disease  
• Full blood count, renal, liver and thyroid function tests, calcium levels, test coeliac serology 
including anti-transglutaminase antibody  
• Serology or a urea breath test for Helicobacter pylori infection (acid suppression medications 
should be stopped for ≥1 week prior to test)  
• Stool tests including fecal calprotectin levels to screen for colonic pathology (colitis, large 
polyps) and fecal occult blood can also be considered; imaging is preferred to fecal elastase to 
detect pancreatic pathology 
• Gastrointestinal endoscopy in presence of alarm features or in patients with persistent 
symptoms despite initial medical management; Even in the absence of macroscopic disease, 
appropriate biopsies are taken to exclude eosinophilic esophagitis (dysphagia), H. pylori 
infection (dyspepsia), celiac disease or sprue (dyspepsia, diarrhea), microscopic colitis 
(diarrhea) 
• Abdominal ultrasonography to exclude gall bladder and other abdominal pathology is routine 
in many European countries; however, diagnostic yield is low unless clinical suspicion of 
specific disorders is present(142, 143)  
• CT should not be routine, especially in young women, to avoid unnecessary exposure to 
radiation 
 
Box 3 | Open research questions 
• The clinical utility of numerical data over pattern recognition in certain tests (e.g. antral 
motility index in gastroparesis, balloon expulsion and rectoanal pressure gradient in 
evacuation disorders) requires further study 
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• Clinical investigations to explain the causes of symptoms in patients with functional 
gastrointestinal disease might require assessment of gastrointestinal structure, motility and 
sensation, which generally requires more than one modality of measurement  
• Current tests of gastrointestinal sensation require validation; new technology and 
methodology are under development to facilitate evaluation of visceral sensitivity in routine 
practice 
• Outcome studies are required to assess indications, based on motility measurements, for 
new therapies (e.g. pyloric botulinum toxin injection, sacral nerve stimulation) 
• Although the usefulness of some gastrointestinal function tests on diagnosis and decisions on 
management have been established, further studies on cost-benefit of physiological 
measurement in clinical practice are warranted 
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Table 1 |: Clinical features of organic versus functional disease  
Patients with ‘organic disease’ with diagnosis based on unique pathology on histology or clinical 
measurement (e.g. neoplasia, inflammation, major motility disorders, severe GERD) and functional 
gastrointestinal diseases with diagnosis based on characteristic symptoms supported by the absence 
of unique pathology on investigations (e.g. dyspepsia, IBS). 
 
Clinical features Organic disease - cause 
evident, secondary to defined 
aetiology 
Functional disease - cause not 
evident, probable primary 
aetiology 
Age  Older (> 45 years) Younger (< 45 years) 
Gender Equal in men and women More common in women than 
men (in caucasian population) 
Timing of consent Defined onset Poorly defined onset 
Symptoms Specific symptoms - pain rarely 
prominent 
Multiple, diffuse symptoms - 
pain often prominent 
Comorbidities No other issues Other functional syndromes 
common 
Psychiatric comorbidities or 
psychological stress 
Equivalent to or slightly 
elevated compared to the 
general population  
Much more common than the 
general population 
Intolerances No history of intolerance to 
medications or diet 
Self-reported intolerance to 
medications and diet 
Therapeutic response Response to specific therapy Poor response to therapy 
Diagnosis and outcome Doctor and patient usually 
satisfied with diagnosis and 
outcome 
Doctor and patients often 
unsatisfied or frustrated with 
diagnosis and outcome due to 
non-specific symptoms and 
lack of specific and effective 
treatments  
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Table 2: Clinical investigation of gastrointestinal motility and function  
Symptom   First Investigation Second Investigation 
Pharyngeal Dysphagia *, chronic 
cough, aspiration, globus 
sensation 
 
Video Fluoroscopic Swallowing 
Exam (VFSE), or ENT 
examination by Fiberoptic 
Endoscopic Evaluation of the 
Swallow (FEES) 
High-Resolution Manometry 
(HRM) ± Impedance, 
± pH-Impedance-Monitoring (if 
reflux disease suspected) 
Esophageal Dysphagia* 
 
HRM ± Impedance, ± 
provocative testing (e.g. rapid 
drink challenge, multiple rapid 
swallows, solid test meal) 
Timed Barium Swallow, ideally 
with fluid and solid material 
Typical and Atypical Reflux 
symptoms, incl. chest pain‡,  
 
HRM ± Impedance, ± 
provocative testing (e.g. rapid 
drink challenge, multiple rapid 
swallows, solid test meal) 
+ pH or pH-Impedance-
Monitoring  
Prolonged catheter-free pH-
monitoring 
Dyspepsia (postprandial 
fullness, bloating, nausea, 
abdomonal pain, weight loss * 
(25% with functional disease) 
„Nutrient Drink Test“, Gastric 
emptying study (Scintigraphy, 
13C- Breath Test) strict 
adherence to standard 
methodology essential. 
HRM ± Impedance + pH-
Impedance-Monitoring (to 
exclude GERD) 
Antroduodenojejunal 
Manometry (to exclude major 
motility disorders) 
Abdominal bloating, chronic 
diarrhea with suspected small 
intestinal bacterial overgrowth 
(SIBO), food intolerance or bile 
acid diarrhea / malabsorption 
Lactose H2-Breath Test if 
intolerance to milk products 
suspected 
Dietary advice with low 
FODMAP or exclusion diet  
 
Glucose or Lactulose H2-Breath 
Test ± oro-caecal transit time 
(validity questioned, see Text  
Endoscopy with aspiration of 
duodenal secretion 
75SeHCAT, C4 or fecal bile acid to 
diagnose bile acid diarrhea 
Intestinal and colonic transit 
time (scintigraphy, wireless 
motility capsule) 
Chronic constipation or 
evacuation disorder 
Anorectal HRM with balloon 
expulsion ± defecography 
(barium or MRI) 
Whole-gut or colon transit time 
(„Sitzmarks test“, scintigraphy, 
wirelesss motility capsule) 
Fecal Incontinence Anorectal HRM, Endoanal 
ultrasonography 
Rectal Barostat 
*Alarm Symptom. Endoscopy or imaging should be performed prior to physiological investigation. 
‡Caution, Ischemic Heart Disease must be excluded prior to physiological investigation. ENT, ear, nose and throat. 
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Figure 1: Gastrointestinal Symptoms of functional gastrointestinal disease. Note that overlap 
between different areas of the GI tract and symptoms can exist. 
 
Figure 2: Management algorithm for patients with functional gastrointestinal symptoms.  
 
Figure 3: Example of Esophageal High-Resolution Manometry with Impedance 
Esophageal motility is assessed by manometry with pressure represented by colors (see scale on right 
(mmHg)). Esophageal function is assessed by impedance measurements that detect the passage of 
fluid or food from the pharynx to the stomach (purple superimposed on manometry image). The water 
swallows show normal motility and function as assessed by the Chicago Classification system. 
Esophageal spasm occurs with the test meal and impedance shows retention of solids in the proximal 
esophagus. This bolus retention is cleared during rapid drink challenge with no evidence of EGJ outlet 
obstruction (or achalasia). 
 
 
Figure 4: Example high-resolution anorectal manometry and endoanal ultrasonography in health and 
faecal incontinence. High-Resolution Anorectal Manometry (upper panel) and Endoanal 
Ultrasonography scans (lower panel) are shown. The structure and function of the healthy anal 
sphincter is shown in a volunteer (left). The muscle layers of the internal and external anal sphincter 
are clearly demonstrated on ultrasonography. Baseline pressure is maintained by tonic contraction of 
the internal sphincter. There is a rapid increase in pressure during voluntary squeeze contraction of 
the external sphincter. Note that the external sphincter extends below the internal sphincter, and this 
facilitates return of any stool in the anal canal to the rectum. The structure and function of the anal 
sphincter is disrupted in a patient with fecal incontinence following an obstetric injury (right). There is 
an acute tear in the external sphincter indicated by white lines at 12 and 2’o-clock positions. This is 
associated with failure to increase pressure during voluntary „squeeze“ seen in the corresponding 
manometry image. Continence function was restored following surgical sphincter repair.  
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